MX2013005796A - Metodos para detectar enfermedades o alteraciones neurodegenerativas. - Google Patents

Metodos para detectar enfermedades o alteraciones neurodegenerativas.

Info

Publication number
MX2013005796A
MX2013005796A MX2013005796A MX2013005796A MX2013005796A MX 2013005796 A MX2013005796 A MX 2013005796A MX 2013005796 A MX2013005796 A MX 2013005796A MX 2013005796 A MX2013005796 A MX 2013005796A MX 2013005796 A MX2013005796 A MX 2013005796A
Authority
MX
Mexico
Prior art keywords
methods
disorders
neurodegenerative diseases
detecting neurodegenerative
detecting
Prior art date
Application number
MX2013005796A
Other languages
English (en)
Inventor
Ryan J Watts
Mark Chen
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2013005796A publication Critical patent/MX2013005796A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
    • A61B6/03—Computed tomography [CT]
    • A61B6/032—Transmission computed tomography [CT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
    • A61B6/03—Computed tomography [CT]
    • A61B6/037—Emission tomography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/50—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications
    • A61B6/501—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications for diagnosis of the head, e.g. neuroimaging or craniography
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Nuclear Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se proveen métodos de identificar, diagnosticar y prognosis de una enfermedad o alteración neurodegenerativa. También se proveen métodos para determinar si una neurona está en riesgo o está sufriendo neurodegeneración.
MX2013005796A 2010-11-29 2011-11-28 Metodos para detectar enfermedades o alteraciones neurodegenerativas. MX2013005796A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41770110P 2010-11-29 2010-11-29
PCT/US2011/062250 WO2012074933A1 (en) 2010-11-29 2011-11-28 Methods for detecting neurodegenerative diseases or disorders

Publications (1)

Publication Number Publication Date
MX2013005796A true MX2013005796A (es) 2013-07-29

Family

ID=46172233

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013005796A MX2013005796A (es) 2010-11-29 2011-11-28 Metodos para detectar enfermedades o alteraciones neurodegenerativas.

Country Status (10)

Country Link
US (1) US20140255301A1 (es)
EP (1) EP2646580A4 (es)
JP (1) JP2014507115A (es)
KR (1) KR20130142144A (es)
CN (1) CN103228799A (es)
BR (1) BR112013012943A2 (es)
CA (1) CA2818010A1 (es)
MX (1) MX2013005796A (es)
RU (1) RU2013129860A (es)
WO (1) WO2012074933A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105403649B (zh) * 2015-12-01 2018-03-20 深圳大学 一种检测ad的尿液多肽组ad生物标记物
WO2018075685A1 (en) * 2016-10-18 2018-04-26 The Regents Of The University Of California Method for positron emission tomography (pet) imaging analysis for classifying and diagnosing of neurological diseases
WO2019071147A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. INHIBITORS OF KINASE P38 REDUCING EXPRESSION OF DUX4 GENE AND DOWNSTREAM GENES FOR THE TREATMENT OF FSHD
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CN109696549B (zh) * 2017-10-20 2022-11-01 成都蓝瑙生物技术有限公司 用于脑中风的发光elisa体外诊断试剂盒
WO2019129029A1 (zh) * 2017-12-29 2019-07-04 北京泱深生物信息技术有限公司 作为帕金森症诊治标志物的基因及其用途
WO2019136300A2 (en) * 2018-01-05 2019-07-11 Immunext, Inc. Anti-mct1 antibodies and uses thereof
CN108377266A (zh) * 2018-02-07 2018-08-07 安徽星网软件技术有限公司 一种基于车联网的实时数据传输方法及系统
US20230210441A1 (en) * 2020-06-01 2023-07-06 Nec Corporation Brain image analysis apparatus, control method, and computer readable medium
CN116626294B (zh) * 2022-09-20 2024-07-09 菲创生物医学技术(广州)有限公司 盘状结构域受体2在诊断神经退行性疾病中的应用及相关的计算机可读介质

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005076939A2 (en) * 2004-02-09 2005-08-25 University Of Kentucky Research Foundation Assay and method for diagnosing and treating alzheimer’s disease

Also Published As

Publication number Publication date
EP2646580A4 (en) 2014-05-14
US20140255301A1 (en) 2014-09-11
JP2014507115A (ja) 2014-03-27
RU2013129860A (ru) 2015-01-10
BR112013012943A2 (pt) 2020-08-11
CN103228799A (zh) 2013-07-31
WO2012074933A1 (en) 2012-06-07
KR20130142144A (ko) 2013-12-27
CA2818010A1 (en) 2012-06-07
EP2646580A1 (en) 2013-10-09

Similar Documents

Publication Publication Date Title
MX2013005796A (es) Metodos para detectar enfermedades o alteraciones neurodegenerativas.
BR112014031365A2 (pt) métodos de detectar doenças ou condições
BR112013001752A2 (pt) método de detectar doenças ou condições usando células fagocídicas
MX358117B (es) Métodos y ácidos nucleicos para determinar el pronóstico de un sujeto con cáncer.
BR112013006683A2 (pt) diagnóstico de câncer de mama
WO2014144121A3 (en) Classification and actionability indices for lung cancer
MX2015006757A (es) Método para la evaluación de la presencia de o riesgo de tumores de colon.
MX349011B (es) Biomarcadores para terapia de inhibidor de hedgehog.
EP2901345A4 (en) GENOME ANALYSIS SYSTEM AND DIAGNOSIS OF GENETIC DISEASE
EP3498729A3 (en) Therapeutic targets for alzheimer's disease
WO2011095623A3 (en) miRNA IN THE DIAGNOSIS OF OVARIAN CANCER
WO2013071119A3 (en) Methods for treating, diagnosing and monitoring alzheimer's disease
WO2012018535A3 (en) Wellness panel
MX2013000916A (es) Metodos para detectar firmas de enfermedad o condiciones en fluidos corporales.
MX2013000502A (es) Metodos y kits para el diagnostico de cancer de prostata.
BR112014031414A2 (pt) métodos de detectar doenças ou condições utilizando células doentes circulantes
MX358474B (es) Biomarcadores salivales específicos para detección de riesgo, diagnóstico temprano, pronóstico y vigilancia de las enfermedades de alzheimer y de parkinson.
WO2011043809A9 (en) Diagnosis, prognosis and identification of potential therapeutic targets of multiple myeloma based on gene expression profiling
EP4202441A3 (en) Gene expression profile in macrophages for the diagnosis of cancer
EP2723866A4 (en) METHOD FOR THE PROGNOSIS AND / OR DIAGNOSIS OF NEURODEEGENERATIVE DISEASES, METHOD FOR IDENTIFYING COMPOUND CANDIDATES AND COMPOUNDS FOR THE TREATMENT OF NEURODEGENATIVE DISEASES
IN2014DN08537A (es)
EP3385717A3 (en) Methods of detecting prostate cancer
WO2013023144A3 (en) Diagnostic biomarker profiles for the detection and diagnosis of parkinsons disease
WO2016145308A3 (en) Whole blood based mrna markers for predicting prostate cancer and methods of detecting the same
IN2014DN08398A (es)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal